|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.97 USD | +6.87% |
|
-1.61% | -12.74% |
| 02-23 | Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion | RE |
| 02-12 | Legend Biotech Shares Lower After Rothschild & Co Redburn Downgrade | MT |
Company Valuation: Legend Biotech Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,735 | 7,175 | 8,357 | 10,938 | 5,969 | 3,504 | 3,504 | - |
| Change | - | 92.11% | 16.46% | 30.89% | -45.43% | -41.31% | 0% | - |
| Enterprise Value (EV) 1 | 3,233 | 6,446 | 7,855 | 9,959 | 4,496 | 3,157 | 2,994 | 2,730 |
| Change | - | 99.39% | 21.86% | 26.78% | -54.85% | -29.79% | -5.16% | -8.8% |
| P/E ratio | -11x | -17x | -17.8x | -20.5x | -33.9x | -11.9x | 63.7x | 10.8x |
| PBR | 13.4x | 15.3x | - | 8.75x | 5.74x | 4.68x | 3.6x | 2.75x |
| PEG | - | -2.42x | -8.13x | -4.1x | 0.5x | -0.2x | -1x | 0x |
| Capitalization / Revenue | 49.4x | 79.9x | 71.4x | 38.4x | 9.52x | 3.39x | 2.39x | 1.93x |
| EV / Revenue | 42.7x | 71.8x | 67.1x | 34.9x | 7.17x | 3.05x | 2.04x | 1.5x |
| EV / EBITDA | -14.6x | -17.9x | -17.7x | -25.4x | -39.7x | -17.7x | 21.9x | 7.43x |
| EV / EBIT | -14.1x | -17.3x | -17.2x | -24.1x | -32.9x | -17.1x | 26.9x | 6.49x |
| EV / FCF | -12x | -26.6x | -33.1x | -24.1x | -28.4x | -26x | 13.2x | 4.54x |
| FCF Yield | -8.31% | -3.76% | -3.02% | -4.15% | -3.52% | -3.85% | 7.55% | 22% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.56 | -2.74 | -2.8 | -2.94 | -0.96 | -1.594 | 0.298 | 1.752 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 75.68 | 89.79 | 117 | 285.1 | 627.2 | 1,035 | 1,466 | 1,817 |
| EBITDA 1 | -220.8 | -360.6 | -443.2 | -392.1 | -113.2 | -178.7 | 136.7 | 367.3 |
| EBIT 1 | -229.2 | -373 | -455.8 | -412.6 | -136.5 | -184.4 | 111.4 | 421 |
| Net income 1 | -303.5 | -386.2 | -446.3 | -518.3 | -177 | -270 | 93.82 | 337.9 |
| Net Debt 1 | -502.3 | -729.5 | -501.5 | -979.4 | -1,473 | -346.8 | -509.6 | -773.2 |
| Reference price 2 | 28.16 | 46.61 | 49.92 | 60.17 | 32.54 | 18.97 | 18.97 | 18.97 |
| Nbr of stocks (in thousands) | 132,638 | 153,946 | 167,403 | 181,789 | 183,451 | 184,690 | 184,690 | - |
| Announcement Date | 18/03/21 | 18/03/22 | 30/03/23 | 11/03/24 | 11/03/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -11.14x | 2.83x | -16.4x | -.--% | 3.28B | |
| 42.29x | 9.88x | 35.66x | 0.03% | 44.3B | |
| 15.95x | 5.66x | 12.46x | 1.87% | 40B | |
| -53.27x | 18x | -59.42x | -.--% | 30.95B | |
| -25.81x | 4.24x | -11.69x | -.--% | 25.58B | |
| 27.26x | 5.62x | 15.59x | -.--% | 18.76B | |
| 22.65x | 4.6x | 16.19x | -.--% | 16.89B | |
| -293.35x | 24.23x | 1418.21x | -.--% | 12.02B | |
| -12.51x | 5937.57x | -16.97x | -.--% | 11.58B | |
| -154.44x | 37.64x | -149.51x | -.--% | 11.03B | |
| Average | -44.24x | 605.03x | 124.41x | 0.19% | 21.44B | |
| Weighted average by Cap. | -20.13x | 331.22x | 73.02x | 0.35% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- LEGN Stock
- Valuation Legend Biotech Corporation
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition